Results 141 to 150 of about 1,114,832 (243)

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Risk factors for renal stone development in adults with primary hyperparathyroidism: a protocol for a systematic review and meta-analysis. [PDF]

BMJ Open
Jay M, Andrei S, Hoang P, Samhat H, Fu R, Jones R, Lipscombe LL, Eskander A.   +7 more
europepmc   +1 more source

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

Design and validation of renal stone detection using multi-architecture feature extraction with deep sequential learning model on axial computed tomography images. [PDF]

Sci Rep
Mansour S, AlOwayyed SA, Eltahir MM, Althobaiti T, Alharkan LA, Almutairi S, Subahi A, Al Sadig M.   +7 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Effect of prior diverse surgical histories on the efficacy and safety of one-stage retrograde intrarenal surgery in patients with renal stone: a retrospective study. [PDF]

Front Urol
Fang D, Mingyuan D, Sun S, Wang H, Wen H.   +4 more
europepmc   +1 more source

Phloroglucinol inhibits human ureteral contractions via activation of cAMP‐PKA pathway

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Phloroglucinol is used to treat renal colic, especially when non‐steroidal anti‐inflammatory drugs are contraindicated. This study aimed to clarify its mechanism by examining effects on human ureteral contractility and underlying signalling pathways. Experimental Approach Urinary levels of neurokinin A (NKA), substance P
Hanwen Liu, Ruize Xu, Zihan Guan, Lei Liu, Guangda Lv, Weibo Chen, Jiliang Wen, Jianing Liu, Jieke Yan, Fangxin Gong, Pan Xiao, Xiulin Zhang, Lei Zhang   +12 more
wiley   +1 more source

RETRACTION: Nephrolithiasis: Molecular Mechanism of Renal Stone Formation and the Critical Role Played by Modulators. [PDF]

Biomed Res Int
International BR.
europepmc   +1 more source

Design and Validation of a Deep Learning Model for Renal Stone Detection and Segmentation on Kidney-Ureter-Bladder Images. [PDF]

Bioengineering (Basel), 2023
Huang ZH, Liu YY, Wu WJ, Huang KW.
europepmc   +1 more source

Structural and biochemical basis for retinol‐binding protein 4 antagonism by tinlarebant

British Journal of Pharmacology, EarlyView.
Background and Purpose Retinol‐binding protein 4 (RBP4) is a member of the lipocalin superfamily that is connected to disease states such as insulin resistance, fatty liver disease and ocular disorders including Stargardt disease. Several retinoid and non‐retinoid antagonists of this protein have been developed for potential clinical use, but none have
Marco Bassetto, Philip D. Kiser
wiley   +1 more source